PM359

About Prime Medicine

Prime Medicine's mission is to deliver on the promise of Prime Editing, a next-generation gene editing technology designed to correct the vast majority of disease-causing mutations with high precision and safety. The company has advanced from foundational research into the clinic, with initial programs for chronic granulomatous disease (CGD) and other indications now generating early human data. Its strategy leverages a single, versatile platform to build a broad pipeline of one-time therapies, aiming to transform treatment paradigms across genetic medicine.

Therapeutic Areas

Other Chronic Granulomatous Disease (CGD) Drugs